Clinical Trial Search

Primary: Cohort 1: Percentage of Participants With Any Local Reactions for up to 7 Days Following Vaccination in Investigational Vaccine Extremity — 74.7; 59.1 Percentage of…

Primary: Proportion of Participants Who Achieved and Maintained Reduction in Serum Uric Acid (sUA) < 6 Milligrams Per Deciliter (mg/dL) for At Least 80% of The Time During…

Primary: Response — 2; 4; 1; 12 Participants

Primary: Change From Baseline in Total Endoscopic Nasal Polyps (NP) Score at Week 52 (Centrally Read) — -0.6; 0.2 Scores on a Scale — p=<0.001

Primary: Psoriatic Arthritis Disease Activity Score (PASDAS) at 24 Weeks — 3.09; 2.70 score on a scale — p=0.064

Primary: Rate of Vaso-occlusive Crises (VOCs) [Adjudicated] Through Week 48 — 1.49; 1.58 Events per 48 weeks — p=0.6967

Primary: Change From Baseline in the Western Ontario Rotator Cuff (WORC) Patient Reported Outcome (PRO) Percentage Score at Week 24 — 55.7; 46.8 Score on a Scale

Primary: Number of Participants With a Change in Mean Distance Control Scores at 3 Months — 1; 0; 4; 4 Participants

Primary: Mean Change in Frequency of Moderate to Severe Hot Flashes (HFs) From Baseline to Week 12 (Assessed by Hot Flash Daily Diary [HFDD]) — 6.71; 6.81; -5.40; -3.50 Number of…

Primary: Part 1: Number of Participants With Dose Limiting Toxicities (DLTs) — 2 Participants

Primary: Number of Participants With First Occurrence of SARS-CoV-2 Reverse Transcription Polymerase Chain Reaction (RT-PCR)-Positive Symptomatic COVID-19 With Onset at Least 14…

Primary: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) — 394 Participants

Primary: Treatment-Emergent Serious Adverse Events (TE-SAEs) of Visual Acuity Decrease — 0; 0 Participants

Primary: Part A: Number of Participants With a First Occurrence of CDC-defined COVID-19 Starting 1 Day After Month 0 Dose Until Month 6 Dose in FAS Cohort Between Analysis Group…

Primary: Percent Change From Baseline in Body Weight — -20.2; -13.7 Percent change